EUVIMEDEUVIMED entdecken
Open Access

Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis

Matthew A Sherman iD, Qingyuan Yang, Laura Gutierrez-Alamillo, Katherine Pak, Willy A Flegel iD, Andrew L Mammen iD, Lisa G Rider iD, Livia A Casciola-Rosen iD, Childhood Myositis Heterogeneity Collaborative Study Group

Arthritis & Rheumatology · 2024

DOI: 10.1002/art.42768 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Matthew A Sherman und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland. Hauptthemen laut MEDLINE: Dermatomyositis, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, Intramural NIH HHS, NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Novel autoantibody specificities including anti‐CCAR1 were recently discovered in adult patients with anti‐transcriptional intermediary factor (TIF1)–positive dermatomyositis (DM) and were associated with attenuated cancer emergence. The aims of the present study were to examine whether these autoantibodies occur in patients with juvenile‐onset DM (JDM) and to determine their associated features.

Methods

Sera from 150 patients with anti‐TIF1γ autoantibody‐positive JDM in a cross‐sectional cohort and 90 juvenile healthy controls were assayed for anti‐CCAR1, anti‐C1Z1, anti‐IMMT, anti‐TBL1XR1, and anti‐Sp4 autoantibodies. Demographics, myositis autoantibodies, clinical features, medications, outcomes, and HLA‐DRB1 and HLA‐DQA1 alleles were compared between those with and without these autoantibodies.

Results

Any one of the anti‐TIF1γ‐associated autoantibodies was present in 44 patients (29%) overall, including 25 (17%) with anti‐Sp4, 22 (15%) with anti‐TBL1XR1, 14 (9%) with anti‐CCAR1, 2 (1%) with anti‐C1Z1, and 2 (1%) with anti‐IMMT autoantibodies. These anti‐TIF1γ‐associated autoantibodies frequently co‐occurred. Patients with any of the anti‐TIF1γ‐associated autoantibodies had less frequent falling (34% [15] vs. 53% [56], P = 0.032) and lower peak muscle enzymes. None of the patients had cancer. Among White patients, HLA‐DRB1*03 was protective against an anti‐TIF1γ‐associated autoantibody (odds ratio 0.20, 95% confidence interval 0.07–0.52).

Conclusion

Autoantibodies associated with anti‐TIF1γ were found in isolation and in combination among a subset of patients with JDM. Patients with these autoantibodies had less severe muscle disease and were not enriched for HLA‐DRB1*03 . Additional autoantibodies among patients with positive anti‐TIF1γ with JDM likely contribute to the heterogeneity of the anti‐TIF1γ serologic subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisNeoplasmsAdultHumansMediation AnalysisHLA-DRB1 ChainsAutoantibodiesCross-Sectional StudiesImmunogeneticsRisk Factors

Substanzen

HLA-DRB1 ChainsAutoantibodies

Autor:innen und Institutionen

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
  • Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • NIH Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, and Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, Maryland.

ORCID-Profile: Matthew A Sherman, Willy A Flegel, Andrew L Mammen, Lisa G Rider, Livia A Casciola-Rosen

Förderung

  • NIAMS NIH HHS
  • Intramural NIH HHS
  • NIEHS NIH HHS
  • Donald B. and Dorothy L. Stabler Foundation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Environmental Health Sciences
  • Clinical Center

Zitieren

APA

Sherman, M. A., Yang, Q., Gutierrez-Alamillo, L., Pak, K., Flegel, W. A., Mammen, A. L., Rider, L. G., Casciola-Rosen, L. A., & Childhood Myositis Heterogeneity Collaborative Study Group (2024). Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis. Arthritis & Rheumatology. https://doi.org/10.1002/art.42768

Vancouver

Sherman MA, Yang Q, Gutierrez-Alamillo L, Pak K, Flegel WA, Mammen AL, et al. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis. Arthritis & Rheumatology. 2024. doi:10.1002/art.42768

BibTeX
@article{Sherman2024,
  author = {Sherman, Matthew A and Yang, Qingyuan and Gutierrez-Alamillo, Laura and Pak, Katherine and Flegel, Willy A and Mammen, Andrew L and Rider, Lisa G and Casciola-Rosen, Livia A and Childhood Myositis Heterogeneity Collaborative Study Group, Childhood Myositis Heterogeneity Collaborative Study Group},
  title = {Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti‐Transcriptional Intermediary Factor 1γ Juvenile‐Onset Dermatomyositis},
  journal = {Arthritis & Rheumatology},
  year = {2024},
  doi = {10.1002/art.42768}
}
Kostenlos starten →